Dr. Reginald D. Gladish, MD
Nephrology (Kidney) (Nephrology Physician)
- Medicare participating
At a glance
- Medical school
- Louisiana State University School of Medicine in Shreveport (1993)
- Years since graduation
- 33
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 674
Licensed in Alabama since 1994, according to the Alabama Board of Medical Examiners and Medical Licensure Commission. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1993Medical school: Louisiana State University School of Medicine in Shreveport
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Nephrology Physician primary
AL license 18219 (first issued 1994; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Marshall Medical Centers Boaz, AL
- Decatur Morgan Hospital - Decatur Campus Decatur, AL
- Athens Limestone Hospital Athens, AL
- Cullman Regional Medical Center Cullman, AL
Medical groups
- Nephrology of North Alabama P.c. (6 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 674
- Services billed
- 4,065
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | 2,035 | 15 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 913 | 237 |
| Dialysis services, 4 or more physician visits per month (20 years or older) | 794 | 112 |
| Established patient office or other outpatient visit, 30-39 minutes | 346 | 264 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 188 | 165 |
| Dialysis services, 2-3 physician visits per month (20 years or older) | 169 | 81 |
| Home dialysis services per month (20 years or older) | 127 | 19 |
| Established patient office or other outpatient visit, 20-29 minutes | 124 | 116 |
| Injection of drug or substance under skin or into muscle | 116 | 15 |
| Blood count, hemoglobin | 97 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Amlodipine Besylate Other prescribers in Decatur, AL | 229 |
| Carvedilol Other prescribers in Decatur, AL | 162 |
| Sevelamer Carbonate Other prescribers in Decatur, AL | 127 |
| Farxiga (dapagliflozin propanediol) Other prescribers in Decatur, AL | 118 |
| Losartan Potassium Other prescribers in Decatur, AL | 114 |
| Gabapentin Other prescribers in Decatur, AL | 94 |
| Hydralazine Hcl Other prescribers in Decatur, AL | 91 |
| Furosemide Other prescribers in Decatur, AL | 86 |
| Ondansetron Hcl Other prescribers in Decatur, AL | 86 |
| Famotidine Other prescribers in Decatur, AL | 79 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 12 companies reported 36 payments worth $830 in total to this clinician.
| Boehringer Ingelheim Pharmaceuticals, Inc. | $197 |
|---|---|
| Akebia Therapeutics Inc | $145 |
| Calliditas Therapeutics US Inc. | $116 |
| Novartis Pharmaceuticals Corporation | $86.21 |
| Travere Therapeutics, Inc. | $55.43 |
| Bayer HealthCare Pharmaceuticals Inc. | $50.12 |
| Novo Nordisk Inc | $48.39 |
| Ani Pharmaceuticals, Inc. | $48.32 |
| Food and Beverage | $821 |
|---|---|
| Education | $9.01 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Akebia Therapeutics Inc Jan 7, 2025 | Education Vafseo · Nephrology · in-kind | $9.01 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $11,793 in research payments for these studies, mostly to the institutions running them.
- Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
Csl Behring · Recruiting · NCT05485961
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.